Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
…sing a longitudinal independent cohort of SLE patients from the Johns Hopkins Lupus Center (JHLC), while their associated cell types were validated using …
…ators to non-initiators and found a similarly increased risk of coronary heart disease to the trial.50 In the original observational study,51 the incl…
…Background In Study 309/KEYNOTE-775 ( NCT03517449), lenvatinib+pembrolizumab versus chemotherapy significantly improved progre…
…were taking an antihypertensive. More than 75% of patients with ischaemic heart disease were taking an antithrombotic or a lipid-lowering agent and mor…
… and 2 by sotagliflozin improves cardiometabolic remodelling in chronic kidney disease, ISHR-ES 2024.…
…their proven efficacy, there remains a gap in the initiation of Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus patients with evidence of coronary …
…), metabolic-associated steatohepatitis (MASH), and the risk of colorectal cancer (CRC) and benign colorectal neoplasms (BCN), and to explore whe…
…, 32% of patients in the US received adjuvant immunotherapy for stage IIB/C melanoma and 21% within our healthcare system. The limited dissemination…
… with an objective response.Conclusions mKRAS-VAX combined with ipilimumab and nivolumab was well-tolerated and resulted in clinical respo…
…cancer (NSCLC) patients with mutated KRAS in a phase 2 trial of mecbotamab vedotin (CAB-AXL-ADC). Presented at: European Lung Cancer Congress; 202…
…esting a reset of the immune switch toward anti-tumor immunity. VP-315 is a promising treatment for non-surgical first line BCC therap…